The RELENT Project
The RELENT Project
The RELENT Project

Economic Impact

Chronic illness requiring long term immunosuppressive treatment and the side effects it entails present a large burden on health care and social systems. Information on actual cost or cost reduction is available for cancer and its treatment, however is very limited for autoimmune diseases. We estimate that more precise monitoring of disease activity, infectious side effects and extending disease free intervals in potentially up to 70% of patients, will not only improve quality of life but substantially reduce cost of health care. RELENT will implement measures to calculate cost-effectiveness and value of different forms of treatment to document the economic impact of the research results.

RELENT Consortium

RELENT Partners
Search
Home
Menu
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

Albert Heck awarded highest scientific distinction in NL Read more

Social Media

TwitterLinkedIn